Article

Body size, dose of hemodialysis, and mortality.

US Renal Data System Coordinating Center, University of Michigan, Ann Arbor, MI, USA.
American Journal of Kidney Diseases (Impact Factor: 5.76). 01/2000; 35(1):80-8. DOI: 10.1016/S0272-6386(00)70305-2
Source: PubMed

ABSTRACT This study investigates the role of body size on the mortality risk associated with dialysis dose in chronic hemodialysis patients. A national US random sample from the US Renal Data System was used for this observational longitudinal study of 2-year mortality. Prevalent hemodialysis patients treated between 1990 and 1995 were included (n = 9,165). A Cox proportional hazards model, adjusting for patient characteristics, was used to calculate the relative risk (RR) for mortality. Both dialysis dose (equilibrated Kt/V [eKt/V]) and body size (body weight, body volume, and body mass index) were independently and significantly (P < 0.01 for each measure) inversely related to mortality when adjusted for age and diabetes. Mortality was less among larger patients and those receiving greater eKt/V. The overall association of mortality risk with eKt/V was negative and significant in all patient subgroups defined by body size and by race-sex categories in the range 0.6 < eKt/V < 1.6. The association was negative in the restricted range 0.9 < eKt/V < 1.6 (although not generally significant) for all body-size subgroups and for three of four race-by-sex subgroups, excepting black men (RR = 1. 003/0.1 eKt/V; P > 0.95). These findings suggest that dose of dialysis and several measures of body size are important and independent correlates of mortality. These results suggest that patient management protocols should attempt to ensure both good patient nutrition and adequate dose of dialysis, in addition to managing coexisting medical conditions.

0 Followers
 · 
117 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCCIÓN Los pacientes con enfermedad renal crónica (ERC) estadio 5 en programa de hemodiálisis (HD) periódica presentan una amplia variedad de síntomas no específicos, que condicionan su bienestar general, para los que muchas veces no es posible determinar una causa orgánica y que, a menudo, no responden adecuadamente a los tratamientos prescritos 1,2,3,4 . Por otra parte, estos pacientes presentan con frecuencia trastornos emocionales como depresión 1,2 , que podrían estar asociados a la mencionada sintomatología y que, en algunos estudios, han demostrado predecir de forma independiente su supervivencia 1,2,3 . La desnutrición es un problema prevalente en HD y condiciona una mala calidad de vida, mayor morbilidad y mortalidad, valorada de manera individual o en el contexto de cuadros de inflamación/malnutrición. Se ha descrito diferentes marcadores de malnutrición en diálisis, tanto bioquímicos como antropométricos que se han asociado a peor calidad de vida en relación a lo anterior con un peor estado emocional 1 . Basados en un trabajo previo de nuestro grupo 1 , en el que observamos una elevada prevalencia de sintomatología afectivo-depresiva en pacientes en hemodiálisis, determinada con la escala de Beck, planteamos este trabajo con los siguientes objetivos: determinar parámetros bioquímicos y clínicos (analíticos y de ganancia de peso entre diálisis), para valorar el estado nutricional, establecer su relación con la presencia de sintomatología depresiva, y conocer la supervivencia a doce meses en pacientes en programa crónico de HD en función de la presencia de sintomatología depresiva y malnutrición.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess residual diuresis and diverse variables according to body mass index (BMI).
  • [Show abstract] [Hide abstract]
    ABSTRACT: An adequate dose of hemodialysis is currently defined by the Kidney Disease Outcomes Quality Initiative (K/DOQI) and European guidelines as a delivered single-pool urea Kt/V (spKt/V) of 1.2 and 1.4, respectively. Results from several studies, in particular the Hemodialysis (HEMO) study, have largely supported the legitimacy of these guidelines, although they may need to be altered or amended for certain patient subgroups. This review discusses several potential changes to current guidelines based on recent clinical outcome studies. The following questions are addressed: 1) Should the dialysis dose for low molecular weight water-soluble solutes (i.e., urea) be normalized by the body distribution volume for urea? 2) Should spKt/V or equilibrated Kt/V (eKt/V) be used for routine monitoring of the hemodialysis dose? 3) Should the dialysis dose for small solutes be dependent on gender? 4) Should the dialysis dose for middle molecules be used in clinical practice? 5) What should be the dialysis dose when using hemodialysis treatment strategies that are more frequent than thrice weekly?
    Seminars in Dialysis 03/2006; 19(2). DOI:10.1111/j.1525-139X.2006.00132.x · 2.07 Impact Factor